Product Description
"
Cobimetinib (GDC-0973, XL-518, Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It was studied in combination with vemurafenib, a BRAF inhibitor, to treat several cancers.
In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib
"
![132112-67-5, Bicyclo[2.2.1]heptane-2,6-dicarbonitrile](https://www.pudeepharm.com/wp-content/uploads/2024/05/675.jpg)
![189253-72-3, (2-{2-[(3-aminopropyl)(methyl)amino]ethoxy}ethyl)dimethylamine](https://www.pudeepharm.com/wp-content/uploads/2024/05/723.jpg)
![835914-81-3, 4-[[4-[[6-[[1-Amino-8-hydroxy-7-[(4-nitro-2-sulfophenyl)azo]-4,6-disulfo-2-naphthalenyl]azo]-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]-2-chloro-6-sulfophenyl]azo]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid, lithium sodium salt](https://www.pudeepharm.com/wp-content/uploads/2024/05/813.jpg)
